DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Votrient (Pazopanib Hydrochloride) - Summary



Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. [See Warnings and Precautions .]



VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI).

VOTRIENT is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

See all Votrient indications & dosage >>


Media Articles Related to Votrient (Pazopanib)

FDA Approves Nivolumab for Renal Cell Carcinoma
Source: Medscape Nephrology Headlines [2015.11.23]
The immunotherapy is the first treatment to show a survival benefit as a second-line therapy in patients with advanced disease.
FDA Approvals

FDA approves Opdivo to treat advanced form of kidney cancer
Source: Cancer / Oncology News From Medical News Today [2015.11.24]
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of...

more news >>

Published Studies Related to Votrient (Pazopanib)

An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. [2014]
study (VEG105192/NCT00334282)... CONCLUSIONS: Efficacy and safety profiles for pazopanib in this extension study

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. [2013]
therapy... CONCLUSIONS: Pazopanib and sunitinib have similar efficacy, but the safety and

Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. [2013]
placebo and to identify predictive patient-specific covariates... CONCLUSIONS: Mathematical modeling of tumor growth kinetics can quantify the

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. [2013]
updated safety results are now reported... INTERPRETATION: Although no significant difference in OS was observed in this

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. [2011.06]
BACKGROUND & AIMS: Pazopanib has demonstrated clinical benefit in patients with advanced renal cell carcinoma (RCC) and is generally well tolerated. However, transaminase elevations have commonly been observed. This 2-stage study sought to identify genetic determinants of alanine transaminase (ALT) elevations in pazopanib-treated white patients with RCC... CONCLUSIONS: The rs2858996/rs707889 polymorphisms in the HFE gene may be associated with reversible ALT elevation in pazo-panib-treated patients with RCC. Copyright (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

more studies >>

Clinical Trials Related to Votrient (Pazopanib)

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer [Recruiting]
The first part of this study is to find the recommended dosages of a combination of two drugs: pazopanib and fosbretabulin, which will be given to female patients with relapsed ovarian cancer. The second part of the study involves comparing the recommended dose of pazopanib and fosbretabulin in combination against pazopanib alone in female patients with relapsed ovarian cancer to determine whether the combination is more beneficial that pazopanib on it's own.

A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma [Recruiting]
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1. 1 and estimate ORR in a separate cohort of patients with angiosarcoma by RECIST 1. 1. Up to 76 patients will be treated in phase 2, including a cohort of up to 13 patients with angiosarcoma.

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer [Active, not recruiting]
This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic RCC. Approximately 160 eligible patients will be stratified based on the ECOG performance status (0 vs. 1) and number of metastatic sites of disease (0 and 1 vs. >=2). The study consists of two treatment periods of 10 weeks with a 2-week wash-out period between the two treatment periods. Patients will receive pazopanib and sunitinib treatment sequentially in a double-blinded fashion. The primary objective of the study is to assess how the tolerability and safety differences between pazopanib and sunitinib translate into patient preference, defined by the patient's stated preference for which drug they may prefer to continue treatment with at end of study. The secondary objectives are to evaluate the reason for patient preference as assessed by a patient preference questionnaire; to evaluate fatigue as assessed by FACIT-Fatigue and quality of life as assessed by EuroQoL EQ-5D; to evaluate dose modifications and time to dose modification; and to evaluate safety.

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma [Recruiting]
The objective of this study is to determine the feasibility of pazopanib treatment interruption with reintroduction at progression in iodine refractory progressive Differentiated Thyroid Cancer (DTC) patients as compared to pazopanib continuous administration.

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied. Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pemetrexed is designed to block proteins that may cause tumors to grow.

more trials >>

Reports of Suspected Votrient (Pazopanib) Side Effects

Death (122)Fatigue (118)Diarrhoea (108)Nausea (92)Hypertension (62)Decreased Appetite (52)Vomiting (51)Drug Ineffective (48)Dyspnoea (37)Blood Pressure Increased (36)more >>

Page last updated: 2015-11-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015